Mitochondrial Transplantation Conference Showcases Positive Advances in Mitochondrial Medicine
MANHASSET, N.Y.--(BUSINESS WIRE)--The first annual Mitochondrial Transplantation and Next Generation Therapeutics Conference, hosted by Northwell Health's Feinstein Institutes for Medical Research, brought together leading scientists, clinicians and innovators in the fields of mitochondrial medicine, transplantation and bioengineering. The three-day conference, held April 27-29 at Hofstra University featured a diverse program of scientific presentations, panel discussions, networking opportunities as well as powerful conversations with advocates, families and patients suffering from mitochondrial diseases.
The conference, led by Lance Becker, MD, professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes, focused on the translational potential of mitochondrial transplantation to address a range of health challenges, from aging and longevity to traumatic brain injury and genetic disorders.
'The growing field of mitochondrial transplantation holds promise for transforming how we treat patients living with some of the most complex diseases – many of whom have no current treatment options,' said Dr. Becker. 'This conference, the first of many more cross-industry conversations, serves as a vital platform for accelerating the translation of cutting-edge research into effective therapies for patients.'
Mitochondrial transplantation is an emerging therapeutic approach aimed at addressing mitochondrial dysfunction by transferring healthy mitochondria into damaged or dysfunctional cells. This innovative technique holds promise for treating a variety of conditions, including genetic mitochondrial diseases, neurodegenerative disorders, ischemia-related injuries and other conditions associated with mitochondrial impairment.
Several hundred attendees from academia, industry and research foundations across the United States, and internationally, convened to discuss topics such as clinical trials for mitochondrial transplantation, novel mitochondrial transfer technologies, therapeutic applications in various disease models (including cardiac arrest, retinal ischemia and cutaneous wounds), and the development of enhanced mitochondrial monitoring and therapeutic strategies.
Key highlights of the summit included keynote presentations by Dr. Becker and James McCully, PhD, associate professor of surgery at Boston Children's Hospital, part of Harvard Medical School, along with focused sessions on translational studies, communicating scientific advancements, and the future of mitochondrial transplantation. Interactive panel discussions explored critical questions in the field and strategies to accelerate innovation and impact. Dedicated poster sessions and networking events fostered collaboration and knowledge exchange among participants.
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
41 minutes ago
- Business Wire
Intradermal Vaccination over Intramuscular Standard of Care
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial. 1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio." Share This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022, 2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support, 3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date. 4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery, 4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. 'This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio,' said Paul LaBarre, Vice President Global Business Development, PharmaJet. 'With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs.' Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial, Vaccines,16 May 2025, 13(5), p.533 2 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025) 3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018. 4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis ® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026.
Yahoo
41 minutes ago
- Yahoo
Publication in Vaccines Highlights Important Benefits of PharmaJet® Tropis® Intradermal Vaccination over Intramuscular Standard of Care
Substantial Improvements in Coverage of IPV2. Vaccine coverage of the second dose of inactivated polio vaccine (IPV2) administered with Tropis ID increased by 11.2% compared to the standard of care (SoC, full dose delivered by needle and syringe intramuscular delivery). On a relative basis, the odds of receiving 2 doses of IPV are doubled when using Tropis ID. Preferred by Vast Majority of Healthcare Workers. Needle-free Tropis ID was the preferred method of vaccination for routine immunization (RI) as reported by 97% of healthcare workers surveyed, who cited that, compared to the SoC, Tropis ID was (i) easier to use (95%), and (ii) children experienced less discomfort (94%). Significant Cost Reductions. Incremental savings with needle-free could range from US$0.07 to US$1.00 per dose, with up to 47% total immunization cost savings compared to the SoC in a full-scale scenario. This equates to a potential savings of ~US$50 million over a 5-year period using Tropis ID for the Nigeria immunization program. GOLDEN, Colo., June 05, 2025--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial.1 The study, funded by a multi-year, US$1.5 million grant from the USAID Development Innovation Ventures Program, in collaboration with the Nigeria National Primary Health Care Development Agency (NPHCDA), Jhpiego, PATH, Sydani Group and Johns Hopkins Bloomberg School of Public Health, aimed to comparatively evaluate the vaccine coverage, cost, feasibility and acceptability of using Tropis ID for fIPV delivery compared to the SoC in a routine immunization program. A household survey was completed in Kano and Oyo States following a six-month implementation with children aged 3 to 12 months. This study is the first to measure coverage benefits of Tropis ID in RI settings, adding to the evidence of the value of needle-free intradermal delivery in the global pursuit of polio eradication. While Nigeria improved full regimen coverage from 33% in 2016 to 57% in 2022,2 it is actively pursuing new approaches that may bring further improvements to coverage and reduce costs as the country prepares for transition from Gavi support,3 while navigating funding reductions in global health programs. Tropis ID, a WHO pre-qualified needle-free delivery system, is an easy-to-use, precise, intradermal delivery method that has already been successfully used in campaign and house-to-house settings in high-risk polio environments, with over 12 million injections administered to date.4 The Vaccines publication highlighted that when compared to the SoC, Tropis ID demonstrated: Increased coverage: IPV2 coverage was 11.2% higher. On a relative basis, this means the odds of receiving 2 doses of IPV are doubled when Tropis ID is used. Cost savings: Up to 47% total immunization costs savings can be realized when using Tropis ID for IPV delivery,4 which equates to a potential savings for the Nigeria immunization program of ~US$50 million over a 5-year period. Acceptability: 97% of healthcare workers preferred Tropis ID for routine immunization, noting it is easy to operate, associated with less perceived discomfort by children during administration, and elicited a positive caregiver response. "This study demonstrates that Tropis ID can improve the patient and caregiver experience over the standard of care for routine immunizations, resulting in increased vaccine compliance, which is an important element in eradicating polio," said Paul LaBarre, Vice President Global Business Development, PharmaJet. "With the added benefits of intradermal dose sparing and the associated cost savings, Tropis ID is an ideal immunization tool. We look forward to collaborating with other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs." Refer to Instructions for Use to ensure safe injections and to review risks. 1 Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria's routine immunization program: An implementation hybrid trial , Vaccines,16 May 2025, 13(5), p.5332 2023: A Critical Year for polio eradication efforts in northern Nigeria. Global Polio Eradication Initiative. 2023. (accessed on 21 March 2025)3 Presentation of Evidence by the Polio Disease Working Group. Presented at the meeting of the Nigerian Immunization Technical Advisory Group, Abuja, Nigeria, 24 July 2018.4 Data on file About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn. About The Global Polio Eradication Strategy (GPEI) In 1988, the Global Polio Eradication Initiative (GPEI) was launched after a resolution passed by the World Health Assembly, with over 350,000 children recorded as having paralytic polio across 125 countries. The GPEI's goals are to detect and stop the spread of poliovirus and strengthen immunization programs globally. Post-eradication strategies, such as sustaining high vaccination rates and strengthening surveillance efforts, are important in the goal of eradicating polio. The GPEI Polio Eradication Strategy 2022–2026 set 2023 as a target year to interrupt all remaining type 1 wild poliovirus (WPV1) transmission (Goal One) and type 2 circulating vaccine-derived poliovirus (cVDPV) transmission (Goal Two), with the aim of reaching eradication by 2026. View source version on Contacts Nancy 1-888-900-4321 Option 3 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Seyltx Expands GluN2B Antagonist Pipeline with Clinical-Stage and Small-Molecule Candidates for Chronic Cough
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seyltx, Inc., ('Seyltx', 'Company') a clinical-stage biotherapeutics company focused on developing therapies to treat chronic cough, today announced it has entered into an option agreement with NeurOp, Inc. ('NeurOp'') for a portfolio of novel GluN2B antagonists. This agreement provides Seyltx with an option to worldwide, exclusive rights to develop and commercialize a portfolio of GluN2B negative allosteric modulators (NAMs) for treating chronic cough in humans, including in refractory chronic cough (RCC) and chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). "We are incredibly excited about this option agreement with NeurOp, which significantly strengthens our pipeline for chronic cough therapies," said Dr. Dietrich A. Stephan, Seyltx's CEO. This strategic agreement combines Seyltx's expertise in chronic cough therapeutic development with NeurOp's expertise in NMDA receptor biology and innovative GluN2B inhibitors. This combination complements and deepens Seyltx's ongoing development of Ifenprodil, a potent NMDA antagonist that is highly selective towards the GluN2B subunit, currently in Phase 2 development. The combined effort is expected to accelerate the development and commercialization of new therapies for chronic cough and solidify Seyltx's position as a leader in addressing this significant unmet medical need. The option agreement includes 8 novel compounds, including NP10679, which has completed Phase 1 and provides Seyltx with a second clinical-phase candidate, with the potential to provide differentiated performance compared to Ifenprodil. These compounds have excellent potency, selectivity, pharmacokinetics, solubility, and metabolism. Strong intellectual property exists across all optioned compounds. "We are incredibly excited about this option agreement with NeurOp, which significantly strengthens our pipeline for chronic cough therapies," said Dr. Dietrich A. Stephan, Seyltx's CEO. "Refractory chronic cough impacts approximately 6 million people in the USA alone, representing a substantial unmet medical need. Furthermore, chronic cough associated with IPF, an orphan condition affecting up to 140,000 people in the US, is a primary driver of deteriorated quality of life for these patients. Our agreement with NeurOp for advanced GluN2B NAMs, particularly NP10679, offers a promising avenue to provide potentially superior treatment options to these patients by addressing the condition with a centrally acting non-narcotic solution." Dr. James McNamara, Executive Chairman of NeurOp added, "NeurOp has been dedicated to advancing novel GluN2B-targeted therapies. This agreement with Seyltx is a testament to the sophistication of our team's expertise in the NMDA receptor biology and the development of our GluN2B antagonists. Seyltx's deep understanding and focus on chronic cough make them an ideal partner to further develop and bring these important compounds to patients in need. We look forward to a very productive partnership." NMDA is a validated therapeutic target in cough, with the only FDA-approved cough therapy being a non-specific NMDA antagonist. Preclinical research has identified the GluN2B subunit of NMDA as a primary target for cough suppression. Traditional non-specific NMDA antagonists have demonstrated limited efficacy due to dose limiting side effects. However, specifically targeting the GluN2B subunit, provides the potential to achieve robust cough suppression, while avoiding the adverse event profile observed with non-specific NMDA antagonists. The addition of NP10679 to the portfolio provides the opportunity to effectively engage the GluN2B receptor, below the safety threshold established in Phase 1, while offering a differentiated selectivity and efficacy profile compared to Ifenprodil. The option agreement has been approved by the management of both companies with a conversion to an exclusive world-wide license agreement anticipated within 12 months. About Seyltx: Seyltx ( is a clinical stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications. Its lead indication is refractory chronic cough, a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). Seyltx's lead compound is Ifenprodil, an NMDA receptor inhibitor highly selective towards the GluN2B subunit, which has completed a Phase 2a trial in chronic cough associated with IPF, with statistically significant reductions in cough from baseline at 12-weeks, and statistically significant improvements on all patient reported outcomes employed. Seyltx is currently progressing into Phase 2 crossover trials. About NeurOp: NeurOp, Inc. is a privately held, clinical-stage biopharmaceutical company based in Atlanta, Georgia that is developing small-molecule therapies for central nervous system disorders, including severe pain, treatment-resistant depression, subarachnoid hemorrhage (SAH) and stroke. Its proprietary compounds selectively inhibit the GluN2B subunit of neuronal NMDA receptors and are designed for potential therapeutic benefit with an improved safety and tolerability profile relative to other NMDA receptor antagonists. Forward-Looking Statements: Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'potential,' 'possible,' 'projects,' 'plans,' and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond Seyltx's control.
